Summary & Overview
CPT 81363: HBB Gene Duplication and Deletion Analysis
CPT code 81363 designates a laboratory service that evaluates genetic duplications and deletions in the hemoglobin, subunit beta (HBB) gene. This molecular diagnostic assay identifies copy number variations that are clinically relevant for inherited hemoglobin disorders and carrier screening. Nationally, accurate identification of HBB gene abnormalities informs diagnosis, family counseling, and therapeutic planning, making this test a critical component of genetic and hematologic care.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The discussion covers payer coverage patterns, clinical context, and operational benchmarks relevant to laboratories and clinicians who order or perform HBB copy number testing.
Readers will learn what CPT code 81363 represents, the typical clinical indications and site of service for the test, and how major payers approach coverage and billing for molecular copy number assays. The publication summarizes common billing considerations, technical service context, and benchmark topics such as test utilization, reimbursement presence across payers, and documentation expectations. Data not available in the input will be noted where applicable.
Billing Code Overview
CPT code 81363 describes a technical laboratory test to detect genetic duplications and deletions in the hemoglobin, subunit beta (HBB) gene. The service involves an experienced laboratory analyst performing molecular laboratory procedures on a patient specimen to evaluate HBB gene copy number variations that can underlie hemoglobinopathies.
Service Type: Genetic diagnostic laboratory test (molecular cytogenetics / copy number analysis)
Typical Site of Service: Clinical diagnostic laboratory or hospital lab (reference or specialty molecular pathology laboratory)
Clinical & Coding Specifications
Clinical Context
A 2-year-old child with microcytic anemia, intermittent jaundice, and a family history of beta-thalassemia presents to a pediatric hematology clinic. Initial evaluation includes a complete blood count, hemoglobin electrophoresis, and iron studies. Abnormal hemoglobin fractions and red cell indices suspicious for a beta-globin disorder prompt genetic testing. A blood specimen is sent to a molecular diagnostics laboratory for analysis of the hemoglobin, subunit beta gene using a targeted duplication/deletion assay. The laboratory technologist performs DNA extraction, assay setup (for example, multiplex ligation-dependent probe amplification or targeted deletion/duplication PCR), data acquisition, and technical interpretation. Report generation includes identification of HBB gene deletions or duplications that explain the phenotype, with results routed to the ordering pediatric hematologist for clinical correlation, genetic counseling, and family cascade testing as indicated. Typical site of service is an outpatient molecular diagnostics laboratory or hospital-based clinical laboratory receiving specimens from ambulatory clinics or inpatient services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting only the professional interpretive component separate from the lab's technical work (rare for this lab-performed CPT). |